TAK1的小分子激活剂促进其活动依赖的泛化和 TRAIL介导的瘤细胞死亡
Weimin Sun1, Guowei Wu1, Xinyu Tian1
1Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 201203, China.
小分子R406/R788激活TAK1 (转化生长因子激活激酶1),增强RIPK1-依赖的细胞死亡. 这些TAK1激活剂通过促进持续的TAK1和RIPK1激活来增强基于TRAIL的癌症疗法.
科学领域:
- 分子生物学分子生物学
- 细胞信号传递 细胞信号传递
- 癌症研究 癌症研究
背景情况:
- 转化生长因子激活激酶1 (TAK1) 对NF-κB和RIPK1信号通路至关重要.
- TAK1激活在TNF信号通路中调解关键酸化事件,影响细胞死亡和存活.
- 向RIPK1-介导的亡是一种癌症治疗的潜在策略.
研究的目的:
- 为了识别激活RIPK1-介导的亡的小分子.
- 研究新型TAK1激活剂的作用机制.
- 评估TAK1激活剂与TRAIL结合用于癌症治疗的治疗潜力.
主要方法:
- 查RIPK1-介导亡的小分子激活剂.
- 生物化学结合测试和点击化学测试以确定TAK1激活机制.
- 评估细胞对TNF介导的亡和亡的敏感性.
- 在体外和体内研究评估与TRAIL的联合治疗.
主要成果:
- 确定R406和R788是促进持续TAK1激活的小分子.
- R406直接结合并激活TAK1,独立于Syk激酶.
- 用R406治疗增强了RIPK1的激活,使细胞对亡和亡敏感.
- R406/R788促进TAK1的无处不在和与RIPK1.1的相互作用.
- 在试验室和小鼠模型中,R406/R788增强了TRAIL的抗癌疗效.
结论:
- 小分子介导TAK1的激活是一种可行的策略,可以增强RIPK1依赖的细胞死亡.
- R406/R788 代表了增强基于 TRAIL 的抗癌疗法的有希望的化合物.
- 向TAK1提供了一种新的方法,使癌细胞对亡和亡敏感.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
相关概念视频
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
